Cellular mechanisms of insulin resistance in humans

被引:0
作者
Shulman, GI
机构
[1] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06536 USA
[2] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06536 USA
[3] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Carbon nuclear magnetic resonance (C-13 NMR) spectroscopy and phosphorus (P-31) NMR spectroscopy have been used to help define the contribution of insulin-stimulated muscle glycogen synthesis to whole-body insulin-stimulated glucose metabolism in normal individuals and the extent to which this process is defective in patients with type 2 (non-insulin-dependent) diabetes. Assessments of the response to hyperglycemic-hyperinsulinemic clamping have shown that abnormalities of muscle glycogen synthesis, apparently mediated by a defect in GLUT-4 transport and/or hexokinase activity, play a major role in causing insulin resistance in type 2 diabetes. Studies of the mechanisms by which free fatty acids (FFA) cause insulin resistance in humans indicate that increased FFA levels inhibit glucose transport, which may be a consequence ai decreased insulin receptor substrate (IRS-l)-associated phosphatidylinositol 3-kinase activity. C-13 NMR spectroscopy studies have documented that liver glycogen concentrations are reduced and the rate of hepatic gluconeogenesis is increased in subjects with type 2 diabetes; thus, the higher rate of glucose production in type 2 diabetes can be attributed entirely to increased rates of hepatic gluconeogenesis. These cellular mechanisms of insulin resistance can be addressed through combination therapy with agents that reverse the principal pathophysiologic defects of type 2 diabetes. The biguanide metformin appears to lower glucose by suppressing hepatic glucose production, whereas the thiazolidinedione troglitazone appears to increase glucose clearance by peripheral tissues. The two agents together have been shown to provide better glucose control than either drug alone, without stimulating insulin secretion. (C) 1999 by Excerpta Medica, Inc.
引用
收藏
页码:3J / 10J
页数:8
相关论文
共 28 条
  • [1] BETA-CELL DEFICIENCY, INSULIN RESISTANCE, OR BOTH
    CAHILL, GF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (19) : 1268 - 1270
  • [2] THE TRIUMVIRATE - BETA-CELL, MUSCLE, LIVER - A COLLUSION RESPONSIBLE FOR NIDDM
    DEFRONZO, RA
    [J]. DIABETES, 1988, 37 (06) : 667 - 687
  • [3] Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity
    Dresner, A
    Laurent, D
    Marcucci, M
    Griffin, ME
    Dufour, S
    Cline, GW
    Slezak, LA
    Andersen, DK
    Hundal, RS
    Rothman, DL
    Petersen, KF
    Shulman, GI
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) : 253 - 259
  • [4] Frayn Keith N., 1993, Current Opinion in Lipidology, V4, P197, DOI 10.1097/00041433-199306000-00004
  • [5] DIMINISHED INSULIN SENSITIVITY AND INCREASED INSULIN-RESPONSE IN NONOBESE, NONDIABETIC MEXICAN-AMERICANS
    HAFFNER, SM
    STERN, MP
    DUNN, J
    MOBLEY, M
    BLACKWELL, J
    BERGMAN, RN
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1990, 39 (08): : 842 - 847
  • [6] Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
    Inzucchi, SE
    Maggs, DG
    Spollett, GR
    Page, SL
    Rife, FS
    Walton, V
    Shulman, GI
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) : 867 - 872
  • [7] THE IMPACT OF METFORMIN THERAPY ON HEPATIC GLUCOSE-PRODUCTION AND SKELETAL-MUSCLE GLYCOGEN-SYNTHASE ACTIVITY IN OVERWEIGHT TYPE-II DIABETIC-PATIENTS
    JOHNSON, AB
    WEBSTER, JM
    SUM, CF
    HESELTINE, L
    ARGYRAKI, M
    COOPER, BG
    TAYLOR, R
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (09): : 1217 - 1222
  • [8] Kobberling J, 1982, GENETICS DIABETES ME, P202
  • [9] IMPAIRED GLUCOSE-TOLERANCE AS A DISORDER OF INSULIN ACTION - LONGITUDINAL AND CROSS-SECTIONAL STUDIES IN PIMA-INDIANS
    LILLIOJA, S
    MOTT, DM
    HOWARD, BV
    BENNETT, PH
    YKIJARVINEN, H
    FREYMOND, D
    NYOMBA, BL
    ZURLO, F
    SWINBURN, B
    BOGARDUS, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (19) : 1217 - 1225
  • [10] Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus - A randomized, double-blind, placebo-controlled trial
    Maggs, DG
    Buchanan, TA
    Burant, CF
    Cline, G
    Gumbiner, B
    Hsueh, WA
    Inzucchi, S
    Kelley, D
    Nolan, J
    Olefsky, JM
    Polonsky, KS
    Silver, D
    Valiquett, TR
    Shulman, GI
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 128 (03) : 176 - 185